SEC Comment Letter 0000000000-24-014266 to ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC.
Date: Dec. 26, 2024 · CIK: 0001513525 · Accession: 0000000000-24-014266
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283968
Letter
December 26, 2024 Cary Claiborne President and Chief Executive Officer Adial Pharmaceuticals, Inc. 4870 Sadler Road, Ste 300 Glen Allen, VA 23060 Re:Adial Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 20, 2024 File No. 333-283968 Dear Cary Claiborne: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Leslie Marlow, Esq.
Show Raw Text
December 26, 2024
Cary Claiborne
President and Chief Executive Officer
Adial Pharmaceuticals, Inc.
4870 Sadler Road, Ste 300
Glen Allen, VA 23060
Re:Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 20, 2024
File No. 333-283968
Dear Cary Claiborne:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Leslie Marlow, Esq.